Anavex Life Sciences annual ebitda
2010
2011
2012
2013
2014
2022
2023
2024
2025
Anavex Life Sciences EBITDA Growth & History (AVXL)
Anavex Life Sciences's calculated EBITDA was −$46.4M for fiscal 2025.
View full Anavex Life Sciences company overviewAnavex Life Sciences annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | −$46.4M | −$3.4M | — |
| 2024 | 2024-09-30 | −$43.0M | $3.5M | — |
| 2023 | 2023-09-30 | −$46.5M | $1.1M | — |
| 2022 | 2022-09-30 | −$47.6M | — | — |
| 2014 | 2014-09-30 | −$3.0M | −$831,416 | — |
| 2013 | 2013-09-30 | −$2.1M | $2.2M | — |
| 2012 | 2012-09-30 | −$4.3M | $1.9M | — |
| 2011 | 2011-09-30 | −$6.2M | −$531,567 | — |
| 2010 | 2010-09-30 | −$5.6M | — | — |
Anavex Life Sciences quarterly ebitda
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | $6.8M | $21.1M | — |
| Q2 2026 | 2026-03-31 | −$6.5M | $6.0M | — |
| Q1 2026 | 2025-12-31 | −$6.8M | $6.8M | — |
| Q4 2025 | 2025-09-30 | −$6.5M | — | — |
| Q3 2025 | 2025-06-30 | −$14.3M | — | — |
| Q2 2025 | 2025-03-31 | −$12.4M | — | — |
| Q1 2025 | 2024-12-31 | −$13.6M | — | — |
| Q3 2015 | 2015-06-30 | −$1.5M | −$514,071 | — |
| Q2 2015 | 2015-03-31 | −$858,090 | $162,885 | — |
| Q1 2015 | 2014-12-31 | −$770,429 | −$461,013 | — |
| Q4 2014 | 2014-09-30 | −$639,175 | $829,232 | — |
| Q3 2014 | 2014-06-30 | −$998,641 | −$872,659 | — |
| Q2 2014 | 2014-03-31 | −$1.0M | −$893,975 | — |
| Q1 2014 | 2013-12-31 | −$309,416 | $105,986 | — |
| Q4 2013 | 2013-09-30 | −$1.5M | −$829,516 | — |
| Q3 2013 | 2013-06-30 | −$125,982 | $571,466 | — |
| Q2 2013 | 2013-03-31 | −$127,000 | $668,141 | — |
| Q1 2013 | 2012-12-31 | −$415,402 | $1.8M | — |
| Q4 2012 | 2012-09-30 | −$638,891 | $587,301 | — |
| Q3 2012 | 2012-06-30 | −$697,448 | $939,313 | — |
| Q2 2012 | 2012-03-31 | −$795,141 | $1.2M | — |
| Q1 2012 | 2011-12-31 | −$2.2M | −$819,499 | — |
| Q4 2011 | 2011-09-30 | −$1.2M | — | — |
| Q3 2011 | 2011-06-30 | −$1.6M | −$334,087 | — |
| Q2 2011 | 2011-03-31 | −$1.9M | — | — |
| Q1 2011 | 2010-12-31 | −$1.4M | — | — |
| Q3 2010 | 2010-06-30 | −$1.3M | — | — |
Anavex Life Sciences ebitda trends
Between the periods ended 2010-09-30 and 2025-09-30, Anavex Life Sciences's ebitda decreased from −$5.6M to −$46.4M, a change of −$40.7M. The latest reported quarter, Q3 2026, shows $6.8M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Anavex Life Sciences source filings ↗